Rosas-Salazar Christian, Gebretsadik Tebeb, Carroll Kecia N, Reiss Sara, Wickersham Nancy, Larkin Emma K, James Kristina M, Miller E Kathryn, Anderson Larry J, Hartert Tina V
Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee.
Department of Biostatistics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee.
Pediatr Allergy Immunol Pulmonol. 2015 Sep 1;28(3):158-164. doi: 10.1089/ped.2015.0528.
Infants with lower respiratory tract infections (LRTIs) are at an increased risk of developing childhood wheezing illnesses (including asthma), but it is not currently possible to predict those at risk for these long-term outcomes. The current objective was to examine whether urine levels of club cell 16-kDa secretory protein (CC16) at the time of an infant LRTI are associated with the development of childhood wheezing illnesses. Prospective study of 133 previously healthy infants enrolled during a healthcare visit for a LRTI and followed longitudinally for childhood wheezing illnesses. Urine levels of CC16 at the time of enrollment were measured after validating a commercially available enzyme-linked immunosorbent assay kit for serum. The outcome of interest was parental report of subsequent childhood wheeze (defined as ≥1 episode of wheezing following the initial LRTI) at the 1-year follow-up visit. Logistic regression was used for the main analysis. The median (interquartile range) urine levels of CC16 (ng/mg of creatinine) at the time of an infant LRTI were 11.1 (7.7-20.1) for infants with subsequent childhood wheeze and 13.4 (8.3-61.1) for those without ( = 0.11). In the main multivariate analysis using a logarithmic transformation of the urine levels of CC16, a twofold increase in urine levels of CC16 was associated with ∼30% decreased odds (OR = 0.74 [95% confidence interval (CI) 0.56-0.98], = 0.04) of subsequent childhood wheeze after adjustment for potential confounders. An inverse association was found between urine levels of CC16 at the time of an infant LRTI and the odds of subsequent childhood wheeze. Urine CC16 may be a useful biomarker of the development of childhood wheezing illnesses after LRTIs in infancy.
患有下呼吸道感染(LRTIs)的婴儿患儿童喘息性疾病(包括哮喘)的风险增加,但目前尚无法预测哪些婴儿有出现这些长期后果的风险。当前的目标是检查婴儿LRTI发作时尿液中克拉拉细胞16 kDa分泌蛋白(CC16)的水平是否与儿童喘息性疾病的发生有关。对133名先前健康的婴儿进行前瞻性研究,这些婴儿因LRTI到医疗机构就诊时被纳入研究,并对其儿童喘息性疾病进行纵向随访。在验证了一种用于血清的商用酶联免疫吸附测定试剂盒后,测量了入组时尿液中CC16的水平。感兴趣的结局是在1年随访时家长报告的儿童随后出现喘息(定义为初始LRTI后≥1次喘息发作)情况。主要分析采用逻辑回归。出现儿童期喘息的婴儿在LRTI发作时CC16的尿液水平中位数(四分位间距)为11.1(7.7 - 20.1)ng/mg肌酐,未出现喘息的婴儿为13.4(8.3 - 61.1)ng/mg肌酐(P = 0.11)。在对CC16尿液水平进行对数转换的主要多变量分析中,调整潜在混杂因素后,CC16尿液水平增加两倍与随后儿童喘息的几率降低约30%相关(比值比[OR] = 0.74[95%置信区间(CI)0.56 - 0.98],P = 0.04)。发现婴儿LRTI发作时尿液中CC16的水平与随后儿童喘息的几率呈负相关。尿液CC16可能是婴儿期LRTI后儿童喘息性疾病发生的有用生物标志物。